NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
OVID
Ovid Therapeutics Inc.
There isn't enough reported data to score OVID yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
OVID Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Weak | |
| Strong |
OVID's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
OVID PE Valuation
OVID has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
OVID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect OVID's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over OVID on earnings quality, reporting a profit while its opponent remains loss making.
OVID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.16 | +$0.33 |
| Q2 2026 | -$0.23 | +$0.29 |
| Q1 2026 | -$0.21 | +$0.13 |
| Q4 2025 | -$0.23 | +$0.14 |
| Q3 2025 | -$0.49 | -$0.03 |
| Q2 2025 | -$0.52 | -$0.10 |
| Q1 2025 | -$0.34 | +$0.38 |
| Q4 2024 | -$0.37 | +$0.37 |
OVID is still losing money, but far less than before: $0.16 per share over the past year, against $1.46 at its worst in mid-2020.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over OVID on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over OVID on profitability, with a higher operating margin.
OVID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $733K | -88% |
| Q4 2025 | $718K | +845% |
| Q3 2025 | $132K | -24% |
| Q2 2025 | $6.3M | +3611% |
| Q1 2025 | $130K | -12% |
| Q4 2024 | $76K | -46% |
| Q3 2024 | $173K | +59% |
| Q2 2024 | $169K | +125% |
OVID's revenue has slid since its 2021 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -2142% | -2061 points |
| Q4 2025 | -1712% | +12396 points |
| Q3 2025 | -9487% | -1842 points |
| Q2 2025 | -81% | +12059 points |
| Q1 2025 | -9654% | +2114 points |
| Q4 2024 | -14108% | -1260 points |
| Q3 2024 | -7645% | +3393 points |
| Q2 2024 | -12140% | +6756 points |
OVID's operating margin was −2142% last quarter, up 7512 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over OVID on cash generation, producing positive trailing cash flow while its opponent burns cash.
OVID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.9M | -$3M |
| Q2 2026 | -$17.6M | -$12.8M |
| Q1 2026 | -$13.9M | -$3.6M |
| Q4 2025 | -$10.4M | -$378K |
| Q3 2025 | -$12.9M | +$2.1M |
| Q2 2025 | -$4.8M | +$9.5M |
| Q1 2025 | -$10.3M | +$6.4M |
| Q4 2024 | -$10M | +$1.9M |
OVID has burned cash in almost every quarter: −$58M over the past year, against −$38M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over OVID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
OVID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.4% | -6.6M shares |
| 1 year | +165% | +118M shares |
| 3 years | +167% | +118M shares |
| 5 years | +178% | +121M shares |
| Available history | +245% | +134M shares |
OVID has 189M diluted shares, up 165% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
OVID Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2021 | -1.5x | Net Cash |
| Q3 2021 | -1.6x | Net Cash |
| Q2 2021 | -1.7x | Net Cash |
| Q1 2021 | -2.0x | Net Cash |
OVID has more cash than debt.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
OVID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.0 | Neutral |
| Stochastic | 62.2 | Neutral |
OVID's weekly RSI is 52 (neutral) and its Stochastic is 62 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
OVID PE vs Healthcare Sector
OVID has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
OVID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.44 | 4.5% above |
| 20 week MA | $2.55 | 0% above |
| 50 week MA | $2.28 | 12% above |
| 100 week MA | $1.53 | 67% above |
| 200 week MA | $2.11 | 21% above |
OVID has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
OVID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.61 | $2.61 | -43% |
| 2021 | $2.61 | $3.39 | +30% |
| 2022 | $3.39 | $1.70 | -50% |
| 2023 | $1.70 | $3.22 | +89% |
| 2024 | $3.22 | $0.97 | -70% |
| 2025 | $0.97 | $1.78 | +84% |
| 2026 YTD | $1.78 | $2.55 | +43% |
OVID has the edge over NVO on returns for 2026, with the stronger performance.